A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Summary

This is a first-in-human,randomized, double-blind, placebo-controlled, single dose escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of AK102 administered subcutaneously in healthy subjects. Subjects will be randomized into 4 planned single dose escalation cohorts or placebo cohort.

Timeline

Start

2018-05-23

Primary completion

2018-11-22

Completion

2018-11-22

Drugs

Indications